Call To Schedule A Clinical Evaluation 1-239-341-5842
menu
close_24px

The Science of Restoring Blood Flow:  Autologous Stem Cell Therapy for Ischemic Disease

ACP-01 is derived from a patient’s own blood and evaluated in clinical research for ischemic conditions, including Heart Failure, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia. 

The Science of Restoring Blood Flow: Autologous Stem Cell Therapy for Ischemic Disease

ACP-01 is derived from a patient’s own blood and evaluated in clinical research for ischemic conditions, including Heart Failure, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia. 

Our Clinical Approach

ACP-01 is an investigational autologous stem cell therapy developed to support circulation in areas affected by ischemic disease. It is derived from a patient’s own blood and evaluated through structured clinical research.

 Autologous Stem Cells 
 
ACP-01 is created using a patient’s own blood. This autologous approach is designed to work in alignment with the body’s natural biological processes.
  
Propietary Technology
 
Cells are isolated and prepared under controlled laboratory conditions before being reintroduced. Each step follows defined clinical protocols.
 
  
Clinical Research
 
 Angogenic Cell Precursors
(ACP-01) have been studied for 20 years in clinical research for vascular and ischemic conditions. Ongoing investigation continues to evaluate safety and clinical outcomes. 
  
 Autologous Source 
 
ACP-01 is created using a patient’s own blood. This autologous approach is designed to work in alignment with the body’s natural biological processes.
  
Careful Preparation
 
Cells are isolated and prepared under controlled laboratory conditions before being reintroduced. Each step follows defined clinical protocols.
 
  
Clinical Research
 
 ACP-01 has been studied in clinical research for vascular and ischemic conditions. Ongoing investigation continues to evaluate safety and clinical outcomes. 
  

Conditions Studied in Clinical Research

ACP-01 has been evaluated in clinical research for select vascular and ischemic conditions. The following areas represent active investigation and research focus

Peripheral Arterial Disease

Peripheral arterial disease affects blood flow to the limbs and may lead to pain, non-healing wounds, or advanced tissue damage. ACP-01 has been studied in clinical research involving patients with advanced PAD.

Learn More About Peripheral Arterial Disease →

 

Chronic Limb Threatening Ischemia

Chronic limb threatening ischemia represents an advanced stage of arterial disease and is associated with significant circulation impairment. ACP-01 has been evaluated in research settings for patients with limited treatment options.

Learn More About Chronic Limb Threatening Ischemia →

 

Vascular Dementia

 

Vascular dementia is associated with reduced blood flow to areas of the brain. ACP-01 is being investigated in clinical research to better understand its potential role in vascular-related cognitive conditions.

Learn More About Vascular Dementia →

 

Cardiovascular Ischemia & Angina

Cardiovascular ischemia refers to impaired coronary blood flow and is associated with angina, ischemic cardiomyopathy, and certain forms of heart failure. ACP-01 is being studied in clinical research for ischemic cardiovascular conditions. 

Learn More About Cardiovascular Ischemia & Angina  →

Information for Patients and Physicians

 Select the pathway most relevant to you. 

1

Patients

Explore investigational therapy information, eligibility considerations, and the clinical evaluation process for advanced vascular and ischemic conditions. 

2

Physicians

 Review published research, study design, and information relevant to physicians managing vascular and ischemic disease. 

Clinical Research and Publications

ACP-01 has been evaluated in structured clinical research for vascular and ischemic conditions. Published findings and ongoing studies continue to assess safety and investigational outcomes.

  • Angiogenic Precursor Cell Treatment of Critical Limb Ischemia Decreases Ulcer Size, Amputation and Death Rate: Re-Examination of phase II ACP NO-CLI Trial Data.

  • Autologous stem cell treatment for CLI patients with no revascularization options: ACP-01 4.5-year clinical update

  • Angiogenic Cell Precursors and Neural Cell Precursors in Service to the Brain-Computer Interface

  • Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages.

  • Safety and outcomes analysis: transcatheter implantation of autologous angiogenic cell precursors for the treatment of cardiomyopathy.

  • Treatment of Patients with Severe Angina Pectoris Using Intracoronarily Injected Autologous Blood-Borne Angiogenic Cell Precursors.

Request Clinical Evaluation  

If you have been diagnosed with an advanced vascular or ischemic condition and are exploring investigational options, you may request further information.

Disclaimer

IMPORTANT NOTICE
 
ACP-01 is an investigational therapy and has not been approved by the U.S. Food and Drug Administration. Information provided on this website is for educational purposes only and does not constitute medical advice. Nothing on this site is intended to promote or market an unapproved therapy. Patients should consult a qualified healthcare professional regarding diagnosis and treatment decisions.
 
FLORIDA NOTICE

This notice is provided in accordance with Florida law. One or more physicians referenced may perform stem cell therapies that have not been approved by the United States Food and Drug Administration. Patients are encouraged to consult with their primary care provider before undergoing any stem cell therapy.